title: Response to 'Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis'.
authors.affiliation: Department of Medical Affairs, MSD Denmark ApS, Lautrupbjerg 4, 2750, Ballerup, Denmark. Nathan.Vastesaeger@merck.com.
authors.forename: Nathan
authors.initials: N
authors.lastname: Vastesaeger
authors.affiliation: UPMC-Paris 6 University, GRC 08, Pierre Louis Institute of Epidemiology and Public Health, 47-83 boulevard de l'Hôpital, 75013, Paris, France. bruno.fautrel@psl.aphp.fr.|AP-HP, Department of Rheumatology, Pitié Salpêtrière Hospital, 47-83 boulevard de l'Hôpital, 75013, Paris, France. bruno.fautrel@psl.aphp.fr.
authors.forename: Bruno
authors.initials: B
authors.lastname: Fautrel
authors.affiliation: Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria. josef.smolen@wienkav.at.
authors.forename: Josef
authors.initials: J
authors.lastname: Smolen
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004359:Drug Therapy, Combination / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*
chemical_list: D018501:Antirheumatic Agents; D008727:Methotrexate